Ngā hua rapu - Bridget A. Robinson
- E whakaatu ana i te 1 - 20 hua o te 24
- Haere ki te Whārangi Whai Ake
-
1
Nonhuman Primate Models of Human Immunology mā Ilhem Messaoudi, Ryan D. Estep, Bridget A. Robinson, Scott W. Wong
I whakaputaina 2010Revisão -
2
-
3
Cisplatin/carboplatin cross-resistance in ovarian cancer mā ME Gore, I Fryatt, E. Wiltshaw, Timothy Dawson, Bridget A. Robinson, A H Calvert
I whakaputaina 1989Artigo -
4
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer mā Ekaterina Volkova, Jinny Willis, J. Elisabeth Wells, Bridget A. Robinson, Gabi U. Dachs, Margaret J. Currie
I whakaputaina 2010Artigo -
5
Mutations of Conserved Residues in the Major Homology Region Arrest Assembling HIV-1 Gag as a Membrane-Targeted Intermediate Containing Genomic RNA and Cellular Proteins mā Motoko Tanaka, Bridget A. Robinson, Kasana Chutiraka, Clair D. Geary, Jonathan C. Reed, Jaisri R. Lingappa
I whakaputaina 2015Artigo -
6
Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels mā Elizabeth J. Campbell, Gabi U. Dachs, Helen Morrin, Valerie Davey, Bridget A. Robinson, Margreet C.M. Vissers
I whakaputaina 2019Artigo -
7
Restoring physiological levels of ascorbate slows tumor growth and moderates HIF‐1 pathway activity in Gulo<sup>−/−</sup> mice mā Elizabeth J. Campbell, Margreet C.M. Vissers, Stephanie M. Bozonet, Arron Dyer, Bridget A. Robinson, Gabi U. Dachs
I whakaputaina 2014Artigo -
8
-
9
The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression mā Vickie Hanrahan, Margaret J. Currie, Sarah Gunningham, Helen Morrin, Prudence A. E. Scott, Bridget A. Robinson, Stephen B. Fox
I whakaputaina 2003Artigo -
10
-
11
Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer mā Caroline Kuiper, Gabi U. Dachs, Delwyn Munn, Margaret J. Currie, Bridget A. Robinson, John F. Pearson, Margreet C.M. Vissers
I whakaputaina 2014Artigo -
12
-
13
-
14
-
15
Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells mā Barry D. Hock, K. A. Mackenzie, Nicholas B. Cross, K. G. Taylor, Margaret J. Currie, Bridget A. Robinson, Jeremy Simcock, Judith L. McKenzie
I whakaputaina 2011Artigo -
16
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised co... mā Timothy Price, Diana Zannino, Kate Wilson, R. J. Simes, J Cassidy, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Niall C. Tebbutt
I whakaputaina 2011Artigo -
17
Deletion of the Monkeypox Virus Inhibitor of Complement Enzymes Locus Impacts the Adaptive Immune Response to Monkeypox Virus in a Nonhuman Primate Model of Infection mā Ryan D. Estep, Ilhem Messaoudi, Megan A. O’Connor, Helen Li, Jerald Sprague, Alex Barron, Flora Engelmann, Bonnie Yen, Michael F. Powers, John M. Jones, Bridget A. Robinson, Beata Orzechowska, Minsha Manoharan, Alfred W. Legasse, Shannon Planer, Jennifer Wilk, Michael K. Axthelm, Scott W. Wong
I whakaputaina 2011Artigo -
18
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX... mā Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, Yujo Chua, John Zalcberg, R. J. Simes, Timothy Price
I whakaputaina 2010Artigo -
19
Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study mā Juan W. Valle, Daniel H. Palmer, Richard Jackson, Trevor F. Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte Rawcliffe, Claudio Bassi, Deborah Stocken, David Cunningham, Derek O’Reilly, David Goldstein, Bridget A. Robinson, Christos S. Karapetis, Andrew Scarfe, F Lacaine, Juhani Sand, Jakob R. Izbicki, Julia Mayerle, Christos Dervenis, Attila Oláh, Giovanni Butturini, Pehr Lind, Mark R. Middleton, Alan Anthoney, Kate Sumpter, Ross Carter, Markus W. Büchler
I whakaputaina 2014Artigo -
20
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy... mā Guy A. Van Hazel, Volker Heinemann, Navesh Sharma, Michael Findlay, Jens Ricke, Marc Peeters, D Díaz Pérez, Bridget A. Robinson, Andrew Strickland, Tom Ferguson, Javier Rodríguez, H. Kröning, Ido Wolf, Vinod Ganju, Euan Walpole, Éveline Boucher, Thomas Tichler, Einat Shacham‐Shmueli, Alex Powell, Paul Eliadis, Richard Isaacs, David Price, Fred M Moeslein, Julien Taı̈eb, G. Bower, Val Gebski, Mark Van Buskirk, David Cade, Kenneth G. Thurston, Peter Gibbs
I whakaputaina 2016Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Cancer
Biology
Oncology
Chemotherapy
Gene
Colorectal cancer
Genetics
Biochemistry
Cancer research
Confidence interval
Gastroenterology
Hazard ratio
Immunology
Surgery
Virology
Virus
Pathology
Bevacizumab
Cell biology
Chemistry
Endocrinology
Environmental health
Immune system
Metastasis
Population
Progression-free survival
Angiogenesis
Ascorbic acid